Opportunities and challenges in the era of molecularly targeted agents and radiation therapy

Journal of the National Cancer Institute

Volumn 105, Issue 10, 2013, Pages 686-693

  Lin, Steven H ^a   George, Thomas J ^b   Ben Josef, Edgar ^c   Bradley, Jeffrey ^d   Choe, Kevin S ^e   Edelman, Martin J ^f   Guha, Chandan ^g   Krishnan, Sunil ^a   Lawrence, Theodore S ^h   Le, Quynh Thu ⁱ   Lu, Bo ^j   Mehta, Minesh ^k   Peereboom, David ^l   Sarkaria, Jann ^m   Seong, Jinsil ⁿ   Wang, Dian ^o   Welliver, Meng X ^p   Coleman, C Norman ^q   Vikram, Bhadrasain ^r   Yoo, Stephen ^r   Chung, Christine H ^s   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j THOMAS JEFFERSON UNIVERSITY   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m MAYO CLINIC   (United States)

ⁿ Yonsei University College of Medicine   (South Korea)

^o MEDICAL COLLEGE OF WISCONSIN   (United States)

^p OHIO STATE UNIVERSITY   (United States)

^q NATIONAL INSTITUTES OF HEALTH   (United States)

^r NATIONAL CANCER INSTITUTE   (United States)

^s JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; AFLIBERCEPT; ANTINEOPLASTIC AGENT; AZACITIDINE; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CABOZANTINIB; CETUXIMAB; CISPLATIN; CRIZOTINIB; DABRAFENIB; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IPILIMUMAB; MK 1775; MK 8776; NIVOLUMAB; NUTLIN 3; SALUMETINIB; TAMOXIFEN; TIVANTINIB; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VEMURAFENIB; VORINOSTAT;

BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; MEDICAL RESEARCH; METHYLATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE I AS TOPIC; CONGRESSES AS TOPIC; CRANIAL IRRADIATION; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; MOLECULAR TARGETED THERAPY; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84877992706     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt055     Document Type: Review

References (23)

1. Mañon RR, Jaradat H, Patel R, et al. Potential for radiation therapy technology innovations to permit dose escalation for non-small-cell lung cancer. Clin Lung Cancer. 2005;7(2):107-113.
2. Liu Y, Li P. Progress in image-guided adaptive radiation therapy. Chinese J Clin Oncol. 2008;35(22):1314-1316, 1320.
3. Mohan R, Bortfeld T. Proton therapy: clinical gains through current and future treatment programs. Front Radiat Ther Oncol. 2011:440-464.
4. Chen AB, Neville BA, Sher DJ, Chen K, Schrag D. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol. 2011;29(17):2305-2311.
5. Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol. 2007;4(3):172-180.
6. Pathak AK, Bhutani M, Saintigny P, Mao L. Heterotransplant mouse model cohorts of human malignancies: a novel platform for systematic preclinical efficacy evaluation of drugs (SPEED). Am J Transl Res. 2009;1(1):16-22.
7. Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012;483(7391):613-617.
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
9. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561- 566.
10. Yasuda H, De Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012;7(7):1086-1090.
11. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19(8):2334-2356.
12. Abe O, Abe R, Enomoto K, et al. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998;351(9114):1451-1467.
13. Li J, Wang Y, Sun Y, Lawrence TS. Wild-type TP53 inhibits G2-phase checkpoint abrogation and radiosensitization induced by PD0166285 a WEE1 kinase inhibitor. Radiat Res. 2002;157(3):322-330.
14. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins Publishing; 2005.
15. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.
16. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol. 2011;29(Suppl):abstract 5500.
17. Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuxi-mab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011;29(17):2312-2318.
18. Ying Kuen C, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56(4):1177-1182.
19. Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol. 2001;61(3):223-231.
20. Esserman LJ, Berry DA, Cheang MC, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on bio-marker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132(3):1049-1062.
21. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery. 2011;1(1):44-53.
22. Albert JM, Cao C, Kwang WK, et al. Inhibition of poly(ADP-ribose) poly-merase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007;13(10):3033-3042.
23. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728-2737.